AU1140495A
(en)
*
|
1994-01-27 |
1995-08-03 |
Bristol-Myers Squibb Company |
Method for preparing thioether conjugates
|
US5658592A
(en)
*
|
1994-05-13 |
1997-08-19 |
Kuraray Co., Ltd. |
Medical crosslinked polymer gel of carboxylic polysaccharide and diaminoalkane
|
US5677470A
(en)
*
|
1994-06-28 |
1997-10-14 |
Tanabe Seiyaku Co., Ltd. |
Baccatin derivatives and processes for preparing the same
|
CA2162759A1
(en)
*
|
1994-11-17 |
1996-05-18 |
Kenji Tsujihara |
Baccatin derivatives and processes for preparing the same
|
US5843903A
(en)
*
|
1995-11-27 |
1998-12-01 |
The Administrators Of The Tulane Educational Fund |
Targeted cytotoxic anthracycline analogs
|
WO1997023243A1
(en)
*
|
1995-12-22 |
1997-07-03 |
Bristol-Myers Squibb Company |
Branched hydrazone linkers
|
CA2251742C
(en)
|
1996-04-15 |
2001-12-11 |
Asahi Kasei Kogyo Kabushiki Kaisha |
Drug complex
|
US6368598B1
(en)
|
1996-09-16 |
2002-04-09 |
Jcrt Radiation Oncology Support Services, Inc. |
Drug complex for treatment of metastatic prostate cancer
|
EP0961619A4
(de)
*
|
1996-09-27 |
2001-09-26 |
Bristol Myers Squibb Co |
Hydrolisierbare prodrugs zur verabreichung von wirkstoffen gegen krebs an metastatische zellen
|
DE19640207A1
(de)
*
|
1996-09-30 |
1998-04-02 |
Bayer Ag |
Glycokonjugate von modifizierten Camptothecin-Derivaten (A- oder B-Ring-Verknüpfung)
|
DK0934329T3
(da)
*
|
1996-09-30 |
2002-04-08 |
Bayer Ag |
Glycokonjugater af modificerede camptothecinderivater (20-O-binding)
|
US5980883A
(en)
*
|
1996-10-02 |
1999-11-09 |
Kuraray Co., Ltd. |
Polymer gel for medical use
|
WO1998019705A1
(en)
|
1996-11-05 |
1998-05-14 |
Bristol-Myers Squibb Company |
Branched peptide linkers
|
ID23424A
(id)
*
|
1997-05-14 |
2000-04-20 |
Bayer Ag |
Glikokonjugat dari 20(s)-kamptotesin
|
EP1033372A4
(de)
*
|
1997-11-18 |
2000-10-04 |
Chugai Pharmaceutical Co Ltd |
Zusammensetzungen mit anti-tumor-aktivität
|
GB9724838D0
(en)
*
|
1997-11-26 |
1998-01-21 |
Franks Christopher R |
Compositions
|
US6204279B1
(en)
*
|
1998-06-03 |
2001-03-20 |
Microcide Pharmaceuticals, Inc. |
Peptidomimetic efflux pump inhibitors
|
AU2337599A
(en)
*
|
1998-01-23 |
1999-08-09 |
Microcide Pharmaceuticals, Inc. |
Efflux pump inhibitors
|
EP1080732A4
(de)
*
|
1998-05-22 |
2004-08-25 |
Daiichi Seiyaku Co |
Medikamentzusammenstellung
|
EP1619210A1
(de)
*
|
1998-10-30 |
2006-01-25 |
Daiichi Pharmaceutical Co., Ltd. |
DDS-Verbindungen und Methoden ihrer Prüfung
|
JP4808846B2
(ja)
*
|
1999-02-24 |
2011-11-02 |
ザ ユーエイビー リサーチ ファンデイション |
癌の標的付けられた治療のためのタキサン誘導体
|
EP1181055A2
(de)
|
1999-05-14 |
2002-02-27 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Enzym-aktivierte antikrebs prodrugverbindungen
|
US6613879B1
(en)
|
1999-05-14 |
2003-09-02 |
Boehringer Ingelheim Pharma Kg |
FAP-activated anti-tumour compounds
|
DE19926475A1
(de)
*
|
1999-06-10 |
2000-12-14 |
Ktb Tumorforschungs Gmbh |
Träger-Pharmaka-Konjugate
|
EP1242401B1
(de)
|
1999-11-24 |
2006-12-27 |
Immunogen, Inc. |
Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung
|
DE10012120A1
(de)
*
|
2000-03-13 |
2001-09-27 |
Ktb Tumorforschungs Gmbh |
Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
|
KR20030014208A
(ko)
|
2000-04-26 |
2003-02-15 |
오레곤 헬스 사이언시즈 유니버시티 |
티올계 화학보호제 화합물의 투여
|
AU7007001A
(en)
|
2000-06-22 |
2002-01-02 |
Nitromed Inc |
Nitrosated and nitrosylated taxanes, compositions and methods of use
|
EP1365803A2
(de)
*
|
2000-08-30 |
2003-12-03 |
Oregon Health and Science University |
Chemoschützende verbindung zur reduzierung der gastrischen toxizität von wirkstoffen
|
US20040018194A1
(en)
*
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
US20070258987A1
(en)
*
|
2000-11-28 |
2007-11-08 |
Seattle Genetics, Inc. |
Recombinant Anti-Cd30 Antibodies and Uses Thereof
|
EP1243276A1
(de)
|
2001-03-23 |
2002-09-25 |
Franciscus Marinus Hendrikus De Groot |
Langgestreckte und mehrfachige Abstandhaltern enthaltende aktivierbare Prodroge
|
EP1383492A4
(de)
|
2001-03-23 |
2008-12-24 |
Napro Biotherapeutics Inc |
Molekulare konjugate zur verwendung in der krebstherapie
|
EP1383538A2
(de)
*
|
2001-04-01 |
2004-01-28 |
YEDA RESEARCH AND DEVELOPMENT CO., Ltd. |
Oral resorbierte arzneimittel
|
DK2163256T3
(en)
|
2001-05-11 |
2015-12-07 |
Ludwig Inst For Cancer Res Ltd |
Specific binding proteins and use thereof
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
EP1434778A4
(de)
|
2001-05-31 |
2005-07-13 |
Medarex Inc |
Cytotoxine und prodrugs, linker und stabilisatoren dafür
|
US7091186B2
(en)
*
|
2001-09-24 |
2006-08-15 |
Seattle Genetics, Inc. |
p-Amidobenzylethers in drug delivery agents
|
EP2363404B8
(de)
|
2001-10-23 |
2016-12-07 |
PSMA Development Company L.L.C. |
PSMA Antikörper
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
US8877901B2
(en)
*
|
2002-12-13 |
2014-11-04 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
US8435529B2
(en)
|
2002-06-14 |
2013-05-07 |
Immunomedics, Inc. |
Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
|
CN1649600A
(zh)
*
|
2002-02-28 |
2005-08-03 |
A&D生物科学公司 |
氟西汀及类似物的糖醛酰胺、苷和原酸酯苷及其应用
|
US8361464B2
(en)
|
2002-03-01 |
2013-01-29 |
Immunomedics, Inc. |
Anthracycline-Antibody Conjugates for Cancer Therapy
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
SG108837A1
(en)
*
|
2002-03-11 |
2005-02-28 |
Pi Eta Consulting Co Pte Ltd |
An enterprise knowledge and information acquisition, management and communications system with intelligent user interfaces
|
US20050107310A1
(en)
*
|
2002-03-19 |
2005-05-19 |
Holick Michael F. |
Carboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
|
WO2003086475A1
(en)
*
|
2002-04-12 |
2003-10-23 |
A & D Bioscience, Inc. |
Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof
|
WO2003086312A2
(en)
*
|
2002-04-12 |
2003-10-23 |
A & D Bioscience, Inc. |
Conjugates comprising cancer cell specific ligands, a sugar and cancer chemotherapeutic agents/boron neutron capture therapy agents, and uses thereof
|
CA2484891A1
(en)
*
|
2002-05-07 |
2003-11-20 |
A & D Bioscience, Inc. |
Conjugates comprising central nervous system active drug
|
US20050215487A1
(en)
*
|
2002-06-27 |
2005-09-29 |
Holick Michael F |
Conjugates comprising an nsaid and a sugar and uses thereof
|
ATE516818T1
(de)
*
|
2002-07-31 |
2011-08-15 |
Seattle Genetics Inc |
Auristatin-konjugate und ihre verwendung zur behandlung von krebs, einer autoimmunkranheit oder einer infektionskrankheit
|
EP1534674A4
(de)
|
2002-08-02 |
2007-11-28 |
Immunogen Inc |
Zytotoxische mittel, die neue, wirkungsvolle taxane enthalten, und deren therapeutische verwendung
|
US7390898B2
(en)
|
2002-08-02 |
2008-06-24 |
Immunogen Inc. |
Cytotoxic agents containing novel potent taxanes and their therapeutic use
|
AU2003288467A1
(en)
*
|
2002-12-13 |
2004-07-09 |
Immunomedics, Inc. |
Immunoconjugates with an intracellularly-cleavable linkage
|
US8420086B2
(en)
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
CA2516455C
(en)
|
2003-02-20 |
2012-05-01 |
Seattle Genetics, Inc. |
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
US20080025989A1
(en)
|
2003-02-20 |
2008-01-31 |
Seattle Genetics, Inc. |
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
CN1777439A
(zh)
*
|
2003-04-22 |
2006-05-24 |
研究及应用科学协会股份有限公司 |
生长抑素的载体
|
US20040219099A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Method for the treatment of tumors
|
US20040220121A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Methods for drug delivery
|
US20040220390A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Composition useful for the treatment of tumors
|
US20040219103A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Methods useful for the diagnosis, imaging and treatment of tumors
|
US20040219100A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Composition useful for the treatment of tumors
|
US20040219104A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Methods for treatment of tumors
|
US20040220084A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Methods for nucleic acid delivery
|
US20040219101A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Composition useful for treatment of tumors
|
US20040219102A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Compositions for drug delivery
|
US20040220085A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Compositions for nucleic acid delivery
|
US20040219097A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Composition useful for the diagnosis, imaging and treatment of tumors
|
US7232805B2
(en)
*
|
2003-09-10 |
2007-06-19 |
Inflabloc Pharmaceuticals, Inc. |
Cobalamin conjugates for anti-tumor therapy
|
EP2486933B1
(de)
|
2003-11-06 |
2015-10-28 |
Seattle Genetics, Inc. |
Mit Antikörpern konjugierte Monomethylvalinverbindungen
|
CA2556752C
(en)
*
|
2004-02-23 |
2016-02-02 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
US7691962B2
(en)
*
|
2004-05-19 |
2010-04-06 |
Medarex, Inc. |
Chemical linkers and conjugates thereof
|
WO2005112919A2
(en)
*
|
2004-05-19 |
2005-12-01 |
Medarex, Inc. |
Self-immolative linkers and drug conjugates
|
UA85716C2
(en)
*
|
2004-05-19 |
2009-02-25 |
Медарекс, Инк. |
Chemical linkers and their conjugates
|
CN114053429A
(zh)
|
2004-06-01 |
2022-02-18 |
健泰科生物技术公司 |
抗体-药物偶联物和方法
|
US7541330B2
(en)
*
|
2004-06-15 |
2009-06-02 |
Kosan Biosciences Incorporated |
Conjugates with reduced adverse systemic effects
|
NZ553500A
(en)
|
2004-09-23 |
2009-11-27 |
Genentech Inc Genentech Inc |
Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
US7641903B2
(en)
*
|
2004-10-15 |
2010-01-05 |
Seattle Genetics, Inc. |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
US8337838B2
(en)
*
|
2004-10-15 |
2012-12-25 |
Seattle Genetics, Inc. |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
CA2583208C
(en)
*
|
2004-10-15 |
2015-08-25 |
Seattle Genetics, Inc. |
Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
AU2005332660A1
(en)
|
2004-11-12 |
2006-12-14 |
Seattle Genetics, Inc. |
Auristatins having an aminobenzoic acid unit at the N terminus
|
DK1827492T3
(da)
|
2004-11-30 |
2010-11-22 |
Curagen Corp |
Antistoffer rettet mod GPNMB og anvendelser deraf
|
US20120269886A1
(en)
|
2004-12-22 |
2012-10-25 |
Nitto Denko Corporation |
Therapeutic agent for pulmonary fibrosis
|
US8173170B2
(en)
|
2004-12-22 |
2012-05-08 |
Nitto Denko Corporation |
Drug carrier and drug carrier kit for inhibiting fibrosis
|
BRPI0607757A2
(pt)
*
|
2005-02-18 |
2009-10-06 |
Medarex Inc |
anticorpo, composição, imunoconjugado, molécula bi-especìfica, molécula de ácido nucleico isolado, vetor de expressão, célula hospedeira, hibridoma, método para preparar um anticorpo anti-psma, e, usos de um anticorpo, ou porção de ligação a antìgeno do mesmo
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US7714016B2
(en)
*
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
AU2006236225C1
(en)
|
2005-04-19 |
2013-05-02 |
Seagen Inc. |
Humanized anti-CD70 binding agents and uses thereof
|
WO2006135371A1
(en)
*
|
2005-06-09 |
2006-12-21 |
Kosan Biosciences Incorporated |
Conjugates with reduced adverse systemic effects
|
DK1912677T3
(da)
*
|
2005-06-20 |
2014-01-13 |
Psma Dev Company L L C |
PSMA-antistof-lægemiddel-konjugater
|
US8871720B2
(en)
*
|
2005-07-07 |
2014-10-28 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
|
ES2708763T3
(es)
|
2005-07-07 |
2019-04-11 |
Seattle Genetics Inc |
Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
|
ATE546160T1
(de)
*
|
2005-09-14 |
2012-03-15 |
Ucb Pharma Sa |
Antikörper-kammpolymer-konjugat
|
WO2007038658A2
(en)
|
2005-09-26 |
2007-04-05 |
Medarex, Inc. |
Antibody-drug conjugates and methods of use
|
ES2527961T3
(es)
*
|
2005-09-26 |
2015-02-02 |
Medarex, L.L.C. |
Anticuerpos monoclonales humanos para CD70
|
JP5116686B2
(ja)
|
2005-10-26 |
2013-01-09 |
メダレックス インコーポレイテッド |
Cc−1065類似体の調製方法及び調製用化合物
|
WO2007102888A2
(en)
*
|
2005-10-28 |
2007-09-13 |
The Regents Of The University Of Colorado |
Methods of treating cancer with doxazolidine and prodrugs thereof
|
WO2007059404A2
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
US9572886B2
(en)
|
2005-12-22 |
2017-02-21 |
Nitto Denko Corporation |
Agent for treating myelofibrosis
|
EP1981527A4
(de)
*
|
2006-01-27 |
2011-05-04 |
Univ Mississippi Medical Ct |
Thermisch gezielte freisetzung von medikamenten, u.a. doxorubicin
|
US7750116B1
(en)
*
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
SG172656A1
(en)
|
2006-05-30 |
2011-07-28 |
Genentech Inc |
Antibodies and immunoconjugates and uses therefor
|
GB0619291D0
(en)
|
2006-09-29 |
2006-11-08 |
Ucb Sa |
Altered antibodies
|
KR101552735B1
(ko)
|
2006-12-01 |
2015-09-14 |
메다렉스, 엘.엘.시. |
씨디22에 결합하는 인간 항체 및 이의 용도
|
ES2523915T5
(es)
|
2006-12-01 |
2022-05-26 |
Seagen Inc |
Agentes de unión a la diana variantes y usos de los mismos
|
CL2007003622A1
(es)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
MX2009006277A
(es)
|
2006-12-14 |
2009-07-24 |
Medarex Inc |
Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
|
TWI412367B
(zh)
|
2006-12-28 |
2013-10-21 |
Medarex Llc |
化學鏈接劑與可裂解基質以及其之綴合物
|
CN101711284A
(zh)
*
|
2007-01-25 |
2010-05-19 |
达娜-法勃肿瘤研究所 |
抗egfr抗体在治疗egfr突变体介导的疾病中的用途
|
CN101616911A
(zh)
|
2007-02-21 |
2009-12-30 |
梅达莱克斯公司 |
具有单个氨基酸的化学连接物及其偶联物
|
WO2008115404A1
(en)
*
|
2007-03-15 |
2008-09-25 |
Ludwing Institute For Cancer Research |
Treatment method using egfr antibodies and src inhibitors and related formulations
|
TWI407971B
(zh)
|
2007-03-30 |
2013-09-11 |
Nitto Denko Corp |
Cancer cells and tumor-related fibroblasts
|
KR20100029764A
(ko)
|
2007-05-16 |
2010-03-17 |
케이티비 투머포슝스케쉘샤프트 엠비에이치 |
저점성 안트라사이클린 제제
|
NZ602024A
(en)
|
2007-07-16 |
2014-04-30 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
JP2010533495A
(ja)
|
2007-07-16 |
2010-10-28 |
ジェネンテック, インコーポレイテッド |
ヒト化CD79b抗体およびイムノコンジュゲートならびにそれらの使用
|
CA2696360C
(en)
|
2007-08-14 |
2018-11-20 |
Ludwig Institute For Cancer Research |
Monoclonal antibody targeting the egfr receptor and uses thereof
|
WO2009026274A1
(en)
|
2007-08-22 |
2009-02-26 |
Medarex, Inc. |
Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
|
WO2009036368A2
(en)
|
2007-09-14 |
2009-03-19 |
Nitto Denko Corporation |
Drug carriers
|
MX2010003581A
(es)
|
2007-10-01 |
2010-08-02 |
Bristol Myers Squibb Co |
Anticuerpos humanos que se adhieren a mesotelina, y usos de los mismos.
|
CA2697992C
(en)
|
2007-10-04 |
2017-08-22 |
Zymogenetics, Inc. |
B7 family member zb7h6 and related compositions and methods
|
CN101903403B
(zh)
*
|
2007-10-19 |
2016-03-16 |
西雅图基因公司 |
Cd19结合剂及其应用
|
ES2450755T3
(es)
*
|
2007-10-19 |
2014-03-25 |
Genentech, Inc. |
Anticuerpos anti-TENB2 modificados por ingeniería genética con cisteína, y conjugados de anticuerpo y fármaco
|
JP5580205B2
(ja)
|
2007-11-19 |
2014-08-27 |
セレラ コーポレーション |
肺癌マーカーとその使用
|
NZ586514A
(en)
*
|
2007-11-30 |
2012-05-25 |
Bristol Myers Squibb Co |
Conjugates of anti-rg-1 antibodies for cancer treatment
|
BRPI0907046A2
(pt)
|
2008-01-18 |
2015-07-28 |
Medimmune Llc |
Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
|
NZ587132A
(en)
|
2008-01-31 |
2012-10-26 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
DK2265283T3
(da)
|
2008-03-18 |
2014-10-20 |
Seattle Genetics Inc |
Auristatin-lægemiddel-linker-konjugater
|
KR20220035504A
(ko)
*
|
2008-04-30 |
2022-03-22 |
이뮤노젠 아이엔씨 |
가교제 및 그 용도
|
PL2282773T3
(pl)
|
2008-05-02 |
2014-08-29 |
Seattle Genetics Inc |
Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
|
ES2438495T3
(es)
|
2008-09-08 |
2014-01-17 |
Psma Development Company, L.L.C. |
Compuestos para exterminar células cancerosas que expresan PSMA, resistentes a taxano
|
UA109633C2
(uk)
|
2008-12-09 |
2015-09-25 |
|
Антитіло людини проти тканинного фактора
|
EP2396036B1
(de)
|
2009-02-13 |
2017-06-28 |
Immunomedics, Inc. |
Immunokonjugate mit einer intrazellulär spaltbaren verknüpfung
|
EA028336B1
(ru)
|
2009-03-05 |
2017-11-30 |
МЕДАРЕКС Л.Л.Си. |
Полностью человеческие антитела, специфические в отношении cadm1
|
EP2414399A1
(de)
|
2009-04-01 |
2012-02-08 |
F. Hoffmann-La Roche AG |
Anti-fcrh5-antikörper und immunkonjugate und anwendungsverfahren
|
SI2437790T1
(sl)
|
2009-06-03 |
2019-07-31 |
Immunogen, Inc. |
Konjugacijske metode
|
AU2010270979B2
(en)
|
2009-06-22 |
2015-04-23 |
Medimmune, Llc |
Engineered Fc regions for site-specific conjugation
|
US8394922B2
(en)
|
2009-08-03 |
2013-03-12 |
Medarex, Inc. |
Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
WO2011047083A1
(en)
|
2009-10-13 |
2011-04-21 |
Oxford Biotherapeutics Ltd. |
Antibodies against epha10
|
TWI483736B
(zh)
|
2009-10-23 |
2015-05-11 |
Millennium Pharm Inc |
抗-gcc抗體分子及其相關之組合物及方法
|
KR20120123299A
(ko)
|
2009-12-04 |
2012-11-08 |
제넨테크, 인크. |
다중특이적 항체, 항체 유사체, 조성물 및 방법
|
WO2011070443A1
(en)
|
2009-12-09 |
2011-06-16 |
Institut National De La Sante Et De La Recherche Medicale |
Monoclonal antibodies that bind b7h6 and uses thereof
|
CA2789230C
(en)
|
2010-02-08 |
2019-04-02 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to 161p2f10b proteins
|
BR112012020373A8
(pt)
|
2010-02-23 |
2018-01-02 |
Genentech Inc |
anticorpo isolado, célula, ácido nucleico isolado, método de identificação, de inibição da proliferação de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína tat419, de diagnóstico da presença de câncer e de distribuição de agente citotóxico
|
WO2011130616A1
(en)
|
2010-04-15 |
2011-10-20 |
Spirogen Limited |
Pyrrolobenzodiazepines used to treat proliferative diseases
|
MX2012011901A
(es)
|
2010-04-15 |
2012-11-29 |
Spirogen Sarl |
Pirrolobenzodiacepinas y conjugados de las mismas.
|
SG10201600791TA
(en)
|
2010-06-08 |
2016-03-30 |
Genentech Inc |
Cysteine engineered antibodies and conjugates
|
PT2580243T
(pt)
|
2010-06-09 |
2020-01-22 |
Genmab As |
Anticorpos contra cd38 humana
|
HUE035599T2
(en)
|
2010-06-15 |
2018-05-28 |
Genmab As |
Human Antibody Pharmacon Conjugate Against Tissue Factor
|
CA2806252C
(en)
|
2010-07-29 |
2019-05-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
ES2680624T3
(es)
|
2010-09-29 |
2018-09-10 |
Agensys, Inc. |
Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
|
EP3828205A1
(de)
|
2010-10-01 |
2021-06-02 |
Oxford BioTherapeutics Ltd |
Anti-ror1-antikörper
|
EP2629801B3
(de)
|
2010-10-22 |
2019-11-27 |
Seattle Genetics, Inc. |
Synergiewirkung zwischen auristatin-basierten antikörper-wirkstoffkonjugaten und hemmern des pi3k-akt-mtor-signalwegs
|
PT3156420T
(pt)
|
2010-12-06 |
2019-05-27 |
Seattle Genetics Inc |
Anticorpos humanizados a liv-1 e seu uso para tratar o cancro
|
MX347298B
(es)
*
|
2010-12-29 |
2017-04-21 |
Arrowhead Res Corp |
Conjugados de suministro de polinucleotidos in vivo que tienen acoplamientos sensibles a enzima.
|
CN103282503B
(zh)
*
|
2010-12-29 |
2015-12-02 |
弗·哈夫曼-拉罗切有限公司 |
用于细胞内递送核酸的小分子缀合物
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
CN103384534B
(zh)
*
|
2011-02-25 |
2015-09-30 |
隆萨有限公司 |
用于蛋白质药物偶联物的支链联接体
|
ES2531471T3
(es)
|
2011-02-25 |
2015-03-16 |
Lonza Ltd |
Enlazador ramificado para conjugados de proteínas-fármacos
|
JP6161592B2
(ja)
|
2011-03-30 |
2017-07-12 |
アリゾナ・ボード・オブ・リージェンツ, フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステート・ユニバーシティArizona Board Of Regents, For And On Behalf Of Arizona State University |
オーリスタチンチラミンリン酸塩およびオーリスタチンアミノキノリン誘導体ならびにそのプロドラッグ
|
JP6177231B2
(ja)
|
2011-04-20 |
2017-08-09 |
ゲンマブ エー/エス |
Her2に対する二重特異性抗体
|
WO2012163805A1
(en)
|
2011-05-27 |
2012-12-06 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) -binding proteins
|
UA112434C2
(uk)
|
2011-05-27 |
2016-09-12 |
Ґлаксо Ґруп Лімітед |
Антигензв'язувальний білок, який специфічно зв'язується з всма
|
EP2723389A2
(de)
|
2011-06-21 |
2014-04-30 |
Immunogen, Inc. |
Neue maytansinoid-derivate mit peptid-linkern und konjugaten davon
|
AU2015224535B2
(en)
*
|
2011-06-21 |
2017-07-20 |
Immunogen, Inc. |
Novel maytansinoid derivatives with peptide linker and conjugates thereof
|
MY160826A
(en)
|
2011-06-28 |
2017-03-31 |
Berlin-Chemie Ag |
Antibodies to bone marrow stromal antigen 1
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
MX341524B
(es)
|
2011-09-20 |
2016-08-24 |
Medimmune Ltd |
Pirrolobenzodiazepinas como compuestos pbd dimericos asimetricos para inclusion en conjugados dirigidos.
|
CA2851534C
(en)
|
2011-10-10 |
2023-02-14 |
Xencor, Inc. |
A method for purifying antibodies
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
JP6393617B2
(ja)
|
2011-10-14 |
2018-09-19 |
シアトル ジェネティクス,インコーポレーテッド |
ピロロベンゾジアゼピンおよび標的コンジュゲート
|
US9399073B2
(en)
|
2011-10-14 |
2016-07-26 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines
|
CN110183470A
(zh)
|
2011-10-14 |
2019-08-30 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓
|
JP6104257B2
(ja)
|
2011-10-14 |
2017-03-29 |
メドイミューン・リミテッドMedImmune Limited |
ピロロベンゾジアゼピンおよびそのコンジュゲート
|
WO2013055993A1
(en)
|
2011-10-14 |
2013-04-18 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
CN109897103A
(zh)
|
2011-11-04 |
2019-06-18 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
HUE053589T2
(hu)
|
2011-11-17 |
2021-07-28 |
Pfizer |
Citotoxikus peptidek és azok antitest-hatóanyag konjugátumai
|
EP3539982A3
(de)
|
2011-12-23 |
2020-01-15 |
Pfizer Inc |
Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
|
WO2013109675A2
(en)
*
|
2012-01-18 |
2013-07-25 |
FIRESTONE, Raymond, A |
Compositions and methods for treating cancer and inflammation-related diseases and conditions
|
CA2862292C
(en)
|
2012-01-20 |
2019-10-08 |
Sea Lane Biotechnologies, Llc |
Binding molecule conjugates
|
PE20141791A1
(es)
|
2012-02-13 |
2014-11-19 |
Bristol Myers Squibb Co |
Compuestos de enediino, conjugados de los mismos y sus usos y metodos
|
US20150335761A1
(en)
*
|
2012-02-16 |
2015-11-26 |
Raymond Firestone |
Compositions and methods for contraception
|
SG11201405130UA
(en)
|
2012-02-24 |
2014-11-27 |
Stemcentrx Inc |
Anti sez6 antibodies and methods of use
|
PL2817338T3
(pl)
|
2012-02-24 |
2017-12-29 |
Abbvie Stemcentrx Llc |
Modulatory DLL3 i sposoby zastosowania
|
CA2864872C
(en)
|
2012-02-24 |
2022-07-05 |
Alteogen Inc. |
Modified antibody in which motif comprising cysteine residue is bound
|
WO2013130093A1
(en)
|
2012-03-02 |
2013-09-06 |
Genentech, Inc. |
Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
|
NZ630020A
(en)
|
2012-03-08 |
2016-08-26 |
Halozyme Inc |
Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
US20140079636A1
(en)
|
2012-04-16 |
2014-03-20 |
Dinesh U. Chimmanamada |
Targeted therapeutics
|
TW201402609A
(zh)
|
2012-05-01 |
2014-01-16 |
Genentech Inc |
抗pmel17抗體及免疫結合物
|
BR112014028222A2
(pt)
|
2012-05-15 |
2017-06-27 |
Seattle Genetics Inc |
conjugados vinculadores auto-estabilizantes.
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
WO2013173391A1
(en)
|
2012-05-15 |
2013-11-21 |
Concortis Biosystems, Corp |
Drug-conjugates, conjugation methods, and uses thereof
|
BR112014028366A2
(pt)
|
2012-05-21 |
2017-06-27 |
Genentech Inc |
anticorpos anti-ly6e e imunoconjugados e métodos de uso
|
WO2013177481A1
(en)
|
2012-05-25 |
2013-11-28 |
Immunogen, Inc. |
Benzodiazepines and conjugates thereof
|
US11180572B2
(en)
|
2012-07-06 |
2021-11-23 |
Genmab B.V. |
Dimeric protein with triple mutations
|
EP3632462A1
(de)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimerprotein mit dreifacher mutation
|
AU2013288932A1
(en)
|
2012-07-09 |
2014-12-11 |
Genentech, Inc. |
Immunoconjugates comprising anti - CD79b antibodies
|
CA2874904A1
(en)
|
2012-07-09 |
2014-01-16 |
Genentech, Inc. |
Immunoconjugates comprising anti-cd22 antibodies
|
IN2014DN10652A
(de)
|
2012-07-09 |
2015-09-11 |
Genentech Inc |
|
CN104540524A
(zh)
|
2012-07-09 |
2015-04-22 |
基因泰克公司 |
包含抗cd22抗体的免疫缀合物
|
CN103566377A
(zh)
|
2012-07-18 |
2014-02-12 |
上海博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
MX2015001399A
(es)
|
2012-08-02 |
2015-09-07 |
Genentech Inc |
Anticuerpos anti-etbr e inmunoconjugados.
|
WO2014022680A1
(en)
|
2012-08-02 |
2014-02-06 |
Genentech, Inc. |
Anti-etbr antibodies and immunoconjugates
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
SG10201701424QA
(en)
|
2012-08-23 |
2017-04-27 |
Agensys Inc |
Antibody drug conjugates (adc) that bind to 158p1d7 proteins
|
KR102052319B1
(ko)
|
2012-10-11 |
2019-12-05 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트
|
ME03486B
(de)
|
2012-10-12 |
2020-01-20 |
Medimmune Ltd |
Pyrrolobenzodiazepine und Konjugate davon
|
US10736903B2
(en)
|
2012-10-12 |
2020-08-11 |
Medimmune Limited |
Pyrrolobenzodiazepine-anti-PSMA antibody conjugates
|
HUE043738T4
(hu)
|
2012-10-12 |
2020-05-28 |
Medimmune Ltd |
Pirrolobenzodiazepinek és konjugátumaik
|
MX364327B
(es)
|
2012-10-12 |
2019-04-23 |
Medimmune Ltd |
Conjugados del anticuerpo pirrolobenzodiazepina - anti-cd22.
|
WO2014057120A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
AU2013328673B2
(en)
|
2012-10-12 |
2017-07-13 |
Medimmune Limited |
Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
|
WO2014057119A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
WO2014057117A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
DK2906253T3
(en)
|
2012-10-12 |
2018-10-22 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine anti-PSMA antibody conjugates
|
US9872924B2
(en)
|
2012-10-19 |
2018-01-23 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate produced by binding through linker having hydrophilic structure
|
US9556192B2
(en)
|
2012-10-30 |
2017-01-31 |
Nerviano Medical Sciences S.R.L. |
Functionalized 9-bromo-camptothecin derivatives
|
JP6355641B2
(ja)
|
2012-11-05 |
2018-07-11 |
ファイザー・インク |
スプライソスタチン類似体
|
JP6133431B2
(ja)
|
2012-11-24 |
2017-05-24 |
ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. |
親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
US10226535B2
(en)
|
2012-12-10 |
2019-03-12 |
Mersana Therapeutics, Inc. |
Auristatin compounds and conjugates thereof
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
DK2900277T3
(da)
|
2012-12-13 |
2022-04-04 |
Immunomedics Inc |
Doser af immunokonjugater af antistoffer og sn-38 til forbedret effektivitet og reduceret toksicitet
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
US9107960B2
(en)
|
2012-12-13 |
2015-08-18 |
Immunimedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
WO2017004144A1
(en)
|
2015-07-01 |
2017-01-05 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
ES2658888T5
(es)
|
2012-12-21 |
2021-10-19 |
Medimmune Ltd |
Pirrolobenzodiazepinas y conjugados de las mismas
|
AU2013364065B2
(en)
*
|
2012-12-21 |
2018-10-04 |
Altrubio Inc. |
Hydrophilic self-immolative linkers and conjugates thereof
|
US9567340B2
(en)
|
2012-12-21 |
2017-02-14 |
Medimmune Limited |
Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
|
KR101597105B1
(ko)
*
|
2013-01-03 |
2016-02-25 |
(주)셀트리온 |
항체-링커-약물 결합체, 그의 제조방법 및 그를 포함하는 항암제 조성물
|
WO2014107024A1
(ko)
|
2013-01-03 |
2014-07-10 |
셀트리온 |
항체-링커-약물 결합체, 그의 제조방법 및 그를 포함하는 항암제 조성물
|
KR101597101B1
(ko)
*
|
2013-01-03 |
2016-02-25 |
(주)셀트리온 |
항체-링커-약물 결합체, 그의 제조방법 및 그를 포함하는 항암제 조성물
|
KR101597100B1
(ko)
*
|
2013-01-03 |
2016-02-25 |
(주)셀트리온 |
항체-링커-약물 결합체, 그의 제조방법 및 그를 포함하는 항암제 조성물
|
KR101597110B1
(ko)
*
|
2013-01-03 |
2016-02-25 |
(주)셀트리온 |
항체-링커-약물 결합체, 그의 제조방법 및 그를 포함하는 항암제 조성물
|
WO2014108198A1
(en)
|
2013-01-10 |
2014-07-17 |
Genmab B.V. |
Human igg1 fc region variants and uses thereof
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
CA3211863A1
(en)
|
2013-01-14 |
2014-07-17 |
Xencor, Inc. |
Novel heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
JP2016513098A
(ja)
|
2013-02-07 |
2016-05-12 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
癌の標的治療用抗体と抱合した極めて強力なプロドラック形態の2−ピロリノドキソルビシン(p2pdox)
|
KR102215954B1
(ko)
|
2013-02-14 |
2021-02-15 |
브리스톨-마이어스 스큅 컴퍼니 |
튜부리신 화합물, 그의 제조 및 사용 방법
|
ITUD20130024A1
(it)
|
2013-02-22 |
2014-08-23 |
Carlo Galli |
Aptameri per la realizzazione di dispositivi biomedicali impiantabili in tessuto e relativo metodo
|
RU2019109456A
(ru)
|
2013-02-22 |
2019-04-10 |
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи |
Новые конъюгаты антител и их применения
|
MX364330B
(es)
|
2013-03-13 |
2019-04-23 |
Medimmune Ltd |
Pirrolobenzodiazepinas y conjugados de las mismas.
|
EA027910B1
(ru)
|
2013-03-13 |
2017-09-29 |
Медимьюн Лимитед |
Пирролобензодиазепины и их конъюгаты
|
EP2968585B1
(de)
|
2013-03-13 |
2018-07-18 |
Medimmune Limited |
Pyrrolobenzodiazepine und konjugate davon
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
KR20150127199A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
항-b7-h4 항체 및 면역접합체
|
WO2014160037A2
(en)
|
2013-03-14 |
2014-10-02 |
The Regents Of The University Of California |
Activatable membrane-interacting peptides and methods of use
|
DK2951203T3
(da)
|
2013-03-15 |
2019-08-12 |
Xencor Inc |
Heterodimere proteiner
|
SG11201507432XA
(en)
|
2013-03-15 |
2015-10-29 |
Abbvie Inc |
Antibody drug conjugate (adc) purification
|
EP2970486B1
(de)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation von t-zellen mit bispezifischen antikörpern und fc-fusionen
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
JP6382935B2
(ja)
|
2013-03-15 |
2018-08-29 |
アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー |
抗egfr抗体薬物複合体製剤
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
EA029818B8
(ru)
|
2013-03-15 |
2018-09-28 |
Займворкс Инк. |
Цитотоксические и антимитотические соединения и способы их применения
|
AU2014262566A1
(en)
|
2013-05-08 |
2015-11-12 |
Zymeworks Inc. |
Bispecific HER2 and HER3 antigen binding constructs
|
SG11201509839TA
(en)
|
2013-05-31 |
2016-01-28 |
Genentech Inc |
Anti-wall teichoic antibodies and conjugates
|
MX369758B
(es)
|
2013-05-31 |
2019-11-20 |
Genentech Inc |
Anticuerpos anti-acido teicoico de pared y conjugados.
|
BR112015030514A2
(pt)
|
2013-06-04 |
2017-08-29 |
Cytomx Therapeutics Inc |
Composições e métodos para conjugação de anticorpos ativáveis
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US9925273B2
(en)
|
2013-08-01 |
2018-03-27 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to CD37 proteins
|
EA201690195A1
(ru)
|
2013-08-12 |
2016-05-31 |
Дженентек, Инк. |
Конъюгатные соединения антитело-лекарство на основе димера 1-(хлорметил)-2,3-дигидро-1h-бензо[e]индола и способы применения и лечения
|
EP3892294A1
(de)
|
2013-08-28 |
2021-10-13 |
AbbVie Stemcentrx LLC |
Konjugationsverfahren stellenspezifischer antikörper und zusammensetzungen
|
WO2015031541A1
(en)
|
2013-08-28 |
2015-03-05 |
Stem Centrx, Inc. |
Novel sez6 modulators and methods of use
|
EP3035938B1
(de)
|
2013-09-10 |
2020-08-19 |
Madrigal Pharmaceuticals, Inc. |
Zielgerichtete therapeutika
|
KR20160055253A
(ko)
|
2013-09-12 |
2016-05-17 |
할로자임, 아이엔씨 |
변형된 항-상피세포 성장인자 수용체 항체 및 이의 사용 방법
|
WO2015038426A1
(en)
*
|
2013-09-13 |
2015-03-19 |
Asana Biosciences, Llc |
Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof
|
WO2015042108A1
(en)
|
2013-09-17 |
2015-03-26 |
Genentech, Inc. |
Methods of using anti-lgr5 antibodies
|
US9956299B2
(en)
|
2013-10-11 |
2018-05-01 |
Medimmune Limited |
Pyrrolobenzodiazepine—antibody conjugates
|
EP4269421A3
(de)
|
2013-10-11 |
2023-12-27 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Tem-8-antikörper und deren verwendung
|
EP3054985B1
(de)
|
2013-10-11 |
2018-12-26 |
Medimmune Limited |
Pyrrolobenzodiazepin-antikörper-konjugate
|
BR112016007402B1
(pt)
|
2013-10-11 |
2023-03-28 |
Oxford Biotherapeutics Ltd |
Anticorpo isolado, ou uma porção de ligação de antígeno deste, composição farmacêutica o compreendendo e seu uso, bem como ácido nucléico, vetor de expressão e método de produção de um anticorpo ou uma porção de ligação de antígeno deste
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
EP3054983B1
(de)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepin-antikörper-konjugate
|
GB201317981D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
MX2016004609A
(es)
|
2013-10-15 |
2016-08-01 |
Seattle Genetics Inc |
Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco.
|
US10836821B2
(en)
|
2013-10-15 |
2020-11-17 |
Sorrento Therapeutics, Inc. |
Drug-conjugates with a targeting molecule and two different drugs
|
JP6908964B2
(ja)
|
2013-10-18 |
2021-07-28 |
ピーエスエムエー ディベロップメント カンパニー,エルエルシー |
Psmaリガンドコンジュゲートによる併用療法
|
US20150110814A1
(en)
|
2013-10-18 |
2015-04-23 |
Psma Development Company, Llc |
Combination therapies with psma ligand conjugates
|
WO2015061209A1
(en)
|
2013-10-21 |
2015-04-30 |
Genentech, Inc. |
ANTI-Ly6E ANTIBODIES AND METHODS OF USE
|
WO2015066053A2
(en)
|
2013-10-28 |
2015-05-07 |
Synta Pharmaceuticals Corp. |
Targeted therapeutics
|
WO2015069922A2
(en)
|
2013-11-06 |
2015-05-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
EP3068892A4
(de)
|
2013-11-13 |
2017-05-31 |
Zymeworks Inc. |
Monovalente antigenbindende konstrukte zum targeting von egfr und/oder her2 und verwendungen davon
|
MX2016006488A
(es)
|
2013-11-21 |
2016-08-03 |
Genmab As |
Formulacion liofilizada de conjugado de anticuerpo-farmaco.
|
MX2016006551A
(es)
|
2013-11-25 |
2016-09-06 |
Seattle Genetics Inc |
Preparacion de anticuerpos de cultivos de celula de ovario de hamster chino para conjugacion.
|
WO2015089344A1
(en)
|
2013-12-13 |
2015-06-18 |
Genentech, Inc. |
Anti-cd33 antibodies and immunoconjugates
|
KR20170042495A
(ko)
|
2013-12-16 |
2017-04-19 |
제넨테크, 인크. |
펩티드모방체 화합물 및 그의 항체-약물 접합체
|
BR112016014126B1
(pt)
|
2013-12-16 |
2023-02-14 |
Medimmune Limited |
Composto não-peptídico, conjugados de anticorpo-fármaco do mesmo, uso dos ditos conjugados para o tratamento de câncer e composição farmacêutica que compreende os mesmos
|
CA2929565A1
(en)
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
|
CA2928952A1
(en)
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
Peptidomimetic compounds and antibody-drug conjugates thereof
|
PL3088419T3
(pl)
|
2013-12-25 |
2019-03-29 |
Daiichi Sankyo Company, Limited |
Koniugat lek-przeciwciało anty-trop2
|
US11560422B2
(en)
*
|
2013-12-27 |
2023-01-24 |
Zymeworks Inc. |
Sulfonamide-containing linkage systems for drug conjugates
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
SG11201605449YA
(en)
|
2014-01-10 |
2016-08-30 |
Birdie Biopharmaceuticals Inc |
Compounds and compositions for immunotherapy
|
MX2016009515A
(es)
|
2014-01-24 |
2016-10-26 |
Genentech Inc |
Metodos para utilizar anticuerpos anti-steap1 e inmunoconjugados.
|
EP3099332A4
(de)
|
2014-01-29 |
2017-06-21 |
Madrigal Pharmaceuticals, Inc. |
Zielgerichtete therapeutika
|
KR102510128B1
(ko)
|
2014-01-31 |
2023-03-14 |
다이이찌 산쿄 가부시키가이샤 |
항-her2 항체-약물 접합체
|
SG11201606898TA
(en)
|
2014-02-21 |
2016-09-29 |
Stemcentrx Inc |
Anti-dll3 antibodies and drug conjugates for use in melanoma
|
PT3122757T
(pt)
|
2014-02-28 |
2023-11-03 |
Hangzhou Dac Biotech Co Ltd |
Ligantes carregados e as suas utilizações em conjugação
|
WO2015134464A2
(en)
|
2014-03-03 |
2015-09-11 |
Synta Pharmaceuticals Corp. |
Targeted therapeutics
|
EP3131586A4
(de)
|
2014-03-18 |
2017-10-25 |
Madrigal Pharmaceuticals, Inc. |
Zielgerichtete therapeutika
|
US9493568B2
(en)
|
2014-03-21 |
2016-11-15 |
Abbvie Inc. |
Anti-EGFR antibodies and antibody drug conjugates
|
AP2016009475A0
(en)
|
2014-03-28 |
2016-09-30 |
Xencor Inc |
Bispecific antibodies that bind to cd38 and cd3
|
EP3125943A4
(de)
|
2014-04-04 |
2017-12-06 |
Merck Sharp & Dohme Corp. |
Phosphatbasierte linker für intrazelluläre verabreichung von arzneimittelkonjugaten
|
KR102239413B1
(ko)
|
2014-04-10 |
2021-04-12 |
다이이찌 산쿄 가부시키가이샤 |
항her3 항체-약물 콘주게이트
|
WO2015155976A1
(ja)
|
2014-04-10 |
2015-10-15 |
第一三共株式会社 |
抗her2抗体-薬物コンジュゲート
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
SG11201608953WA
(en)
|
2014-04-30 |
2016-11-29 |
Pfizer |
Anti-ptk7 antibody-drug conjugates
|
EP3145952A2
(de)
|
2014-05-22 |
2017-03-29 |
Genentech, Inc. |
Anti-gpc3-antikörper und immunkonjugate
|
JP6453706B2
(ja)
*
|
2014-05-23 |
2019-01-16 |
日本化薬株式会社 |
新規なグルタミン酸誘導体およびその用途
|
JP6539729B2
(ja)
*
|
2014-06-03 |
2019-07-03 |
ジアリー・ファーマシューティカルズ・インコーポレイテッドJiaray Pharmaceuticals, Inc. |
ペプチド−薬物複合体
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
CN106661124A
(zh)
|
2014-06-20 |
2017-05-10 |
荷商台医(有限合伙)公司 |
抗叶酸受体α(FRA)抗体‑药物缀合物及其使用方法
|
EP3682904A1
(de)
|
2014-06-30 |
2020-07-22 |
Glykos Finland Oy |
Saccharidderivat einer toxischen nutzlast und antikörperkonjugate davon
|
CA2952758A1
(en)
|
2014-07-11 |
2016-01-14 |
Genmab A/S |
Antibodies binding axl
|
EP3194449A1
(de)
|
2014-07-24 |
2017-07-26 |
Xencor, Inc. |
Schnelle beseitigung von antigenkomplexen unter verwendung neuartiger antikörper
|
CN106536540A
(zh)
|
2014-07-24 |
2017-03-22 |
基因泰克公司 |
将试剂缀合至含有至少一个三硫键的蛋白质中的巯基部分的方法
|
KR20230172625A
(ko)
|
2014-08-28 |
2023-12-22 |
바이오아트라, 인코퍼레이티드 |
변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체
|
KR102051503B1
(ko)
|
2014-08-28 |
2019-12-03 |
화이자 인코포레이티드 |
항체 약물 접합체에 사용하기 위한 안정성-조정 링커
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
EP3193940A1
(de)
|
2014-09-10 |
2017-07-26 |
Medimmune Limited |
Pyrrolobenzodiazepine und konjugate daraus
|
PL3191502T3
(pl)
|
2014-09-11 |
2021-11-08 |
Seagen Inc. |
Ukierunkowane dostarczanie substancji leczniczych zawierających aminę trzeciorzędową
|
CN114106185A
(zh)
|
2014-09-12 |
2022-03-01 |
基因泰克公司 |
抗her2抗体和免疫缀合物
|
EP3191518B1
(de)
|
2014-09-12 |
2020-01-15 |
Genentech, Inc. |
Anti-b7-h4-antikörper und immunkonjugate
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
CN107108724A
(zh)
|
2014-09-12 |
2017-08-29 |
豪夫迈·罗氏有限公司 |
半胱氨酸改造抗体和缀合物
|
SG10201804931QA
(en)
|
2014-09-12 |
2018-07-30 |
Genentech Inc |
Anti-cll-1 antibodies and immunoconjugates
|
EP3197500A1
(de)
|
2014-09-17 |
2017-08-02 |
Genentech, Inc. |
Immunkonjugate mit anti-her2-antikörpern und pyrrolobenzodiazepinen
|
SG11201702143PA
(en)
|
2014-09-17 |
2017-04-27 |
Zymeworks Inc |
Cytotoxic and anti-mitotic compounds, and methods of using the same
|
AU2015320678B2
(en)
|
2014-09-23 |
2021-07-22 |
Genentech, Inc. |
Method of using anti-CD79b immunoconjugates
|
EP3215513B1
(de)
|
2014-11-05 |
2019-05-08 |
Nerviano Medical Sciences S.r.l. |
Funktionalisierte morpholinyl-anthracyclin-derivate
|
US10077287B2
(en)
|
2014-11-10 |
2018-09-18 |
Bristol-Myers Squibb Company |
Tubulysin analogs and methods of making and use
|
CA2966964A1
(en)
|
2014-11-19 |
2016-05-26 |
Michal Novak |
Humanized tau antibodies in alzheimer's disease
|
CN106170303B
(zh)
*
|
2014-11-20 |
2019-10-25 |
法罗斯根有限公司 |
通过半胱天冬酶激活的前体药物
|
NZ731782A
(en)
|
2014-11-25 |
2023-04-28 |
Medimmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
RS62332B1
(sr)
|
2014-11-26 |
2021-10-29 |
Xencor Inc |
Heterodimerna antitela koja vezuju cd3 i cd20
|
BR112017011166A2
(pt)
|
2014-11-26 |
2018-02-27 |
Xencor, Inc. |
anticorpos heterodiméricos que se ligam a cd3 e cd38
|
CN107206101B
(zh)
|
2014-12-03 |
2021-06-25 |
基因泰克公司 |
季铵化合物及其抗体-药物缀合物
|
MX2017007055A
(es)
|
2014-12-03 |
2017-11-08 |
Genentech Inc |
Conjugados de anticuerpo rifamicina anti-staphylococcus aureus y usos de estos.
|
BR112017011478A2
(pt)
|
2014-12-03 |
2018-02-27 |
Genentech, Inc. |
composto de conjugado anticorpo-antibiótico, conjugado anticorpo-antibiótico, composição farmacêutica, métodos de tratamento de uma infecção bacteriana e para exterminar staph aureus, processo para a preparação do composto, kit e intermediário antibiótico-ligante
|
WO2016091891A1
(en)
|
2014-12-09 |
2016-06-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies against axl
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
TW201632532A
(zh)
|
2015-01-14 |
2016-09-16 |
必治妥美雅史谷比公司 |
伸雜芳基-橋聯苯并二氮呯二聚體,其共軛物及製造及使用方法
|
ES2918425T3
(es)
|
2015-01-28 |
2022-07-15 |
Sorrento Therapeutics Inc |
Conjugados de anticuerpo-fármaco
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
WO2016141230A1
(en)
|
2015-03-05 |
2016-09-09 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
LT3268047T
(lt)
|
2015-03-09 |
2023-11-10 |
Heidelberg Pharma Research Gmbh |
Amatoksino-antikūno konjugatai
|
TWI719967B
(zh)
|
2015-03-09 |
2021-03-01 |
美商艾澤西公司 |
結合至flt3蛋白之抗體藥物結合物(adc)
|
EP3069734A1
(de)
|
2015-03-17 |
2016-09-21 |
Exiris S.r.l. |
Cryptophycinbasierte antikörper-arzneimittelkonjugate mit neuartigen selbstimmolativen verbindern
|
JP6869187B2
(ja)
|
2015-04-07 |
2021-05-12 |
メモリアル スローン ケタリング キャンサー センター |
ナノ粒子イムノコンジュゲート
|
GB201506389D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
AU2016252771B2
(en)
|
2015-04-22 |
2021-12-16 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
|
EP3091033A1
(de)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3-antikörper und verwendungen davon
|
BR112017025719A2
(pt)
*
|
2015-05-29 |
2018-08-07 |
Arrowhead Pharmaceuticals Inc |
agentes de ligação tetrapeptídicos biologicamente cliváveis
|
JP7269733B2
(ja)
|
2015-06-12 |
2023-05-09 |
レンティジェン・テクノロジー・インコーポレイテッド |
操作されたt細胞を用いて癌を処置するための方法
|
AR104987A1
(es)
|
2015-06-15 |
2017-08-30 |
Genentech Inc |
Inmunoconjugados anticuerpo-fármaco unidos por enlazadores no peptídicos
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
WO2017002776A1
(ja)
|
2015-06-29 |
2017-01-05 |
第一三共株式会社 |
抗体-薬物コンジュゲートの選択的製造方法
|
CN108368171A
(zh)
|
2015-07-10 |
2018-08-03 |
根马布股份公司 |
用于癌症治疗的axl特异性抗体-药物缀合物
|
CA2991973C
(en)
|
2015-07-12 |
2021-12-07 |
Suzhou M-Conj Biotech Co., Ltd. |
Bridge linkers for conjugation of a cell-binding molecule
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
WO2017019489A1
(en)
|
2015-07-24 |
2017-02-02 |
George Robert Pettit |
Quinstatin compounds
|
EP3347047A1
(de)
|
2015-09-09 |
2018-07-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Expressionsvektor-abgabesystem und dessen verwendung zur induzierung einer immunantwort
|
US10800826B2
(en)
|
2015-10-05 |
2020-10-13 |
Merck Sharp & Dohme Corp. |
Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
|
WO2017062271A2
(en)
|
2015-10-06 |
2017-04-13 |
Merck Sharp & Dohme Corp. |
Antibody drug conjugate for anti-inflammatory applications
|
WO2017062748A1
(en)
|
2015-10-07 |
2017-04-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
|
WO2017060397A1
(en)
|
2015-10-09 |
2017-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from melanoma metastases
|
CN114181960A
(zh)
|
2015-10-09 |
2022-03-15 |
美天施生物科技有限公司 |
嵌合抗原受体和使用方法
|
WO2017067944A1
(en)
|
2015-10-19 |
2017-04-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from triple negative breast cancer
|
US11793880B2
(en)
|
2015-12-04 |
2023-10-24 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
WO2017096311A1
(en)
|
2015-12-04 |
2017-06-08 |
Seattle Genetics, Inc. |
Conjugates of quaternized tubulysin compounds
|
US11623957B2
(en)
|
2015-12-07 |
2023-04-11 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
SG11201805557SA
(en)
|
2016-01-08 |
2018-07-30 |
Bioalliance Cv |
Tetravalent anti-psgl-1 antibodies and uses thereof
|
US20190030180A1
(en)
|
2016-01-13 |
2019-01-31 |
Genmab A/S |
Formulation for antibody and drug conjugate thereof
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
WO2017132103A2
(en)
|
2016-01-29 |
2017-08-03 |
Merck Sharp & Dohme Corp. |
Phosphonate linkers and their use to facilitate cellular retention of compounds
|
CA3012960A1
(en)
|
2016-02-01 |
2017-08-10 |
Pfizer Inc. |
Tubulysin analogs and methods for their preparation
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
WO2017139623A1
(en)
|
2016-02-10 |
2017-08-17 |
Immunomedics, Inc. |
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
|
EP3419655A1
(de)
|
2016-02-27 |
2019-01-02 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Peptidimpfstoffe mit selbstanordnenden polymernanopartikeln
|
EP3423112A4
(de)
*
|
2016-02-29 |
2020-02-26 |
Madrigal Pharmaceuticals, Inc. |
Hsp9-inhibitor-wirkstoff-konjugate
|
WO2017151947A1
(en)
|
2016-03-02 |
2017-09-08 |
George Robert Pettit |
4-azapodophylotoxins compounds
|
PE20231049A1
(es)
|
2016-03-02 |
2023-07-11 |
Eisai Randd Man Co Ltd |
Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
|
EP3222292A1
(de)
|
2016-03-03 |
2017-09-27 |
Heidelberg Pharma GmbH |
Amanitinkonjugate
|
MA45324A
(fr)
|
2016-03-15 |
2019-01-23 |
Seattle Genetics Inc |
Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
|
BR112018068461A2
(pt)
|
2016-03-15 |
2019-01-22 |
Mersana Therapeutics Inc |
conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
CN107216392A
(zh)
*
|
2016-03-17 |
2017-09-29 |
华东师范大学 |
蟾蜍毒素衍生物的抗体药物偶联物及其制备方法和应用
|
WO2017162678A1
(en)
|
2016-03-22 |
2017-09-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Humanized anti-claudin-1 antibodies and uses thereof
|
WO2017165851A1
(en)
|
2016-03-25 |
2017-09-28 |
Seattle Genetics, Inc. |
Process for the preparation of pegylated drug-linkers and intermediates thereof
|
EP3442574A4
(de)
|
2016-04-15 |
2019-12-11 |
MacroGenics, Inc. |
Neuartige b7-h3-bindende moleküle, antikörper-wirkstoff-konjugate davon und verfahren zur verwendung davon
|
SG11201808994YA
(en)
|
2016-04-15 |
2018-11-29 |
Bioatla Llc |
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
CA3021098A1
(en)
|
2016-04-21 |
2017-10-26 |
Abbvie Stemcentrx Llc |
Novel anti-bmpr1b antibodies and methods of use
|
US11016085B2
(en)
|
2016-04-25 |
2021-05-25 |
The Johns Hopkins University |
ZNT8 assays for drug development and pharmaceutical compositions
|
CA3016917A1
(en)
|
2016-04-27 |
2017-11-02 |
Immunomedics, Inc. |
Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
WO2017197045A1
(en)
|
2016-05-11 |
2017-11-16 |
Movassaghi Mohammad |
Convergent and enantioselective total synthesis of communesin analogs
|
SI3455261T1
(sl)
|
2016-05-13 |
2023-01-31 |
Bioatla, Inc. |
Protitelesa proti ROR2, fragmenti protitelesa, njihovi imunokonjugati in uporabe le-teh
|
EP3458101B1
(de)
|
2016-05-20 |
2020-12-30 |
H. Hoffnabb-La Roche Ag |
Protac-antikörper-konjugate und verfahren zur verwendung
|
US10639378B2
(en)
|
2016-06-06 |
2020-05-05 |
Genentech, Inc. |
Silvestrol antibody-drug conjugates and methods of use
|
BR112018075653A2
(pt)
|
2016-06-08 |
2019-08-27 |
Abbvie Inc |
anticorpos anti-b7-h3 e conjugados anticorpo fármaco
|
JP2019521973A
(ja)
|
2016-06-08 |
2019-08-08 |
アッヴィ・インコーポレイテッド |
抗bh7−h3抗体及び抗体薬物コンジュゲート
|
MX2018015274A
(es)
|
2016-06-08 |
2019-10-07 |
Abbvie Inc |
Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
|
JP6751165B2
(ja)
|
2016-06-08 |
2020-09-02 |
アッヴィ・インコーポレイテッド |
抗b7−h3抗体及び抗体薬物コンジュゲート
|
EP3468599A2
(de)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-cd98-antikörper und antikörperwirkstoffkonjugate
|
CN110352070A
(zh)
|
2016-06-14 |
2019-10-18 |
Xencor股份有限公司 |
双特异性检查点抑制剂抗体
|
AU2017204139B2
(en)
|
2016-06-17 |
2018-08-09 |
Magenta Therapeutics, Inc. |
Compositions and methods for the depletion of cells
|
EP4050032A1
(de)
|
2016-06-28 |
2022-08-31 |
Xencor, Inc. |
Somatostatin-rezeptor 2 bindende heterodimere antikörper
|
AU2017290705B2
(en)
|
2016-06-29 |
2021-08-26 |
Rascal Therapeutics, Inc. |
Compounds and compositions for the treatment of cancer
|
WO2018005697A1
(en)
|
2016-06-29 |
2018-01-04 |
The Regents Of The University Of California |
Antibodies specific to sonic hedgehog and method of use thereof
|
US11712480B2
(en)
|
2016-08-03 |
2023-08-01 |
Pfizer Inc. |
Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
|
EA201990470A1
(ru)
|
2016-08-09 |
2019-09-30 |
Сиэтл Дженетикс, Инк. |
Конъюгаты лекарственного средства с самостабилизирующимися линкерами, имеющие улучшенные физико-химические свойства
|
CN109641911B
(zh)
|
2016-08-19 |
2023-02-21 |
百时美施贵宝公司 |
seco-环丙吡咯并吲哚化合物和其抗体-药物缀合物以及制备和使用方法
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
WO2018045245A1
(en)
|
2016-09-02 |
2018-03-08 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
JP7160482B2
(ja)
|
2016-09-02 |
2022-10-25 |
レンティジェン・テクノロジー・インコーポレイテッド |
Duocarを用いてがんを処置するための組成物および方法
|
EP3522933B1
(de)
|
2016-10-05 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Verfahren zur herstellung von antikörperarzneimittelkonjugaten
|
EP3526240A1
(de)
|
2016-10-14 |
2019-08-21 |
Xencor, Inc. |
Bispezifische heterodimere fusionsproteine mit il-15/il-15ralpha fc-fusionsproteinen und pd-1-antikörperfragmenten
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
JP2019530697A
(ja)
|
2016-10-18 |
2019-10-24 |
シアトル ジェネティックス, インコーポレイテッド |
ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤の標的化送達
|
WO2018075842A1
(en)
|
2016-10-20 |
2018-04-26 |
Bristol-Myers Squibb Company |
Condensed benzodiazepine derivatives and conjugates made therefrom
|
CA3080270A1
(en)
|
2016-10-25 |
2018-05-03 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Monoclonal antibodies binding to the cd160 transmembrane isoform
|
US20190276549A1
(en)
|
2016-11-01 |
2019-09-12 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
CN116143678A
(zh)
|
2016-11-14 |
2023-05-23 |
杭州多禧生物科技有限公司 |
偶联连接体,含有此连接体的细胞结合分子-药物偶联物及其制备和应用
|
KR102221364B1
(ko)
|
2016-11-21 |
2021-03-04 |
쿠레아브 게엠베하 |
항-gp73 항체 및 면역접합체
|
SG10201912575RA
(en)
|
2016-12-12 |
2020-02-27 |
Daiichi Sankyo Co Ltd |
Combination of antibody-drug conjugate and immune checkpoint inhibitor
|
CN110099698B
(zh)
|
2016-12-23 |
2023-02-17 |
海德堡医药研究有限责任公司 |
鹅膏蕈碱抗体缀合物
|
AU2018205372B2
(en)
|
2017-01-09 |
2020-08-06 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-mesothelin immunotherapy
|
WO2018135501A1
(ja)
|
2017-01-17 |
2018-07-26 |
第一三共株式会社 |
抗gpr20抗体及び抗gpr20抗体-薬物コンジュゲート
|
MX2019008205A
(es)
|
2017-01-20 |
2020-01-23 |
Magenta Therapeutics Inc |
Composiciones y metodos para el agotamiento de células cd137+.
|
JP2020505034A
(ja)
|
2017-01-20 |
2020-02-20 |
ジュノ セラピューティクス ゲーエムベーハー |
細胞表面コンジュゲートならびに関連する細胞組成物および方法
|
CN110300765A
(zh)
|
2017-01-24 |
2019-10-01 |
依奈特制药公司 |
Nkp46结合剂
|
SG11201906414VA
(en)
|
2017-01-24 |
2019-08-27 |
Pfizer |
Calicheamicin derivatives and antibody drug conjugates thereof
|
US20200023071A1
(en)
|
2017-02-06 |
2020-01-23 |
Innate Pharma |
Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
|
NZ754810A
(en)
|
2017-02-08 |
2023-04-28 |
Medimmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
JP7341060B2
(ja)
|
2017-02-10 |
2023-09-08 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Mapk経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
|
TW201834697A
(zh)
|
2017-02-28 |
2018-10-01 |
美商梅爾莎納醫療公司 |
Her2標靶抗體-藥物結合物之組合療法
|
AU2018227146A1
(en)
|
2017-02-28 |
2019-08-29 |
Daiichi Sankyo Company, Limited |
Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate
|
JP2020510432A
(ja)
|
2017-03-02 |
2020-04-09 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Nectin−4への特異性を有する抗体及びその使用
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
CN112695050A
(zh)
|
2017-03-24 |
2021-04-23 |
莱蒂恩技术公司 |
用于用抗cd33免疫疗法治疗癌症的组合物和方法
|
EP3600443A1
(de)
|
2017-03-24 |
2020-02-05 |
Seattle Genetics, Inc. |
Verfahren zur herstellung von glucuronidwirkstoff-linkern und zwischenprodukten davon
|
RU2758234C2
(ru)
|
2017-03-27 |
2021-10-26 |
Иммьюномедикс, Инк. |
ЛЕЧЕНИЕ ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ХАРАКТЕРИЗУЮЩЕГОСЯ ЭКСПРЕССИЕЙ Trop-2, С ПОМОЩЬЮ САЦИТУЗУМАБА ГОВИТЕКАНА И ИНГИБИТОРА Rad51
|
CN110352201A
(zh)
|
2017-04-03 |
2019-10-18 |
免疫医疗公司 |
用于癌症疗法的抗体药物缀合物的皮下施用
|
JP2020515629A
(ja)
|
2017-04-04 |
2020-05-28 |
アヴィディア テクノロジーズ, インコーポレイテッド |
免疫応答を誘導するためのペプチドベースのワクチン、それらの製造方法および使用
|
MX2019012017A
(es)
|
2017-04-07 |
2020-02-12 |
Juno Therapeutics Inc |
Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
|
SI3612537T1
(sl)
|
2017-04-18 |
2022-10-28 |
Medimmune Limited |
Konjugati pirolobenzodiazepina
|
WO2018195302A1
(en)
|
2017-04-19 |
2018-10-25 |
Bluefin Biomedicine, Inc. |
Anti-vtcn1 antibodies and antibody drug conjugates
|
US20200129637A1
(en)
|
2017-04-20 |
2020-04-30 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
MX2019012194A
(es)
|
2017-04-27 |
2019-12-16 |
Seattle Genetics Inc |
Conjugados inhibidores de la via de recuperacion de dinucleotido de nicotinamida adenina cuaternizados.
|
AU2018259856A1
(en)
|
2017-04-28 |
2019-11-14 |
Ajinomoto Co., Inc. |
Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof
|
TW202330036A
(zh)
|
2017-05-15 |
2023-08-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物之製造方法
|
UA127900C2
(uk)
|
2017-06-14 |
2024-02-07 |
Ейдісі Терапьютікс Са |
Схема дозування для введення adc до cd19
|
JP2020524156A
(ja)
|
2017-06-20 |
2020-08-13 |
マドリガル ファーマシューティカルズ インコーポレイテッドMadrigal Pharmaceuticals,Inc. |
標的治療薬を含む併用療法
|
IL299893A
(en)
|
2017-06-20 |
2023-03-01 |
Madrigal Pharmaceuticals Inc |
prescribed medications
|
WO2018234843A1
(en)
|
2017-06-22 |
2018-12-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS WITH AGENTS CAPABLE OF INHIBITING THE ACTIVATION OF MOSES-ASSOCIATED INVARIANT T CELLS (MAIT)
|
EP3645122A1
(de)
|
2017-06-30 |
2020-05-06 |
Xencor, Inc. |
Zielgerichtete heterodimere fc-fusionsproteine mit il-15/il-15ra und antigenbindenden domänen
|
CN111316099A
(zh)
|
2017-07-12 |
2020-06-19 |
约翰霍普金斯大学 |
用于1型糖尿病诊断的基于脂蛋白体的znt8自身抗原
|
CA3071624A1
(en)
|
2017-07-31 |
2019-02-07 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy
|
US10487084B2
(en)
|
2017-08-16 |
2019-11-26 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
|
US10508115B2
(en)
|
2017-08-16 |
2019-12-17 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
|
US10472361B2
(en)
|
2017-08-16 |
2019-11-12 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
|
US10494370B2
(en)
|
2017-08-16 |
2019-12-03 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
|
US10457681B2
(en)
|
2017-08-16 |
2019-10-29 |
Bristol_Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
|
HRP20220311T1
(hr)
|
2017-08-18 |
2022-05-13 |
Medimmune Limited |
Konjugati pirolobenzodiazepina
|
KR20240018674A
(ko)
|
2017-08-31 |
2024-02-13 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트의 신규 제조 방법
|
EP4279086A3
(de)
|
2017-09-15 |
2024-02-28 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit anti-cd19-immuntherapie
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
US10543263B2
(en)
|
2017-10-16 |
2020-01-28 |
Lentigen Technology Inc. |
Compositions and methods for treating cancer with anti-CD22 immunotherapy
|
US11312770B2
(en)
|
2017-11-08 |
2022-04-26 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
SG11202004698RA
(en)
|
2017-11-30 |
2020-06-29 |
Seattle Genetics Inc |
Process for the preparation of drug linker compounds
|
EP3498293A1
(de)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Behandlung monogener erkrankungen mit einem anti-cd45rc-antikörper
|
JP2021506260A
(ja)
|
2017-12-15 |
2021-02-22 |
ジュノー セラピューティクス インコーポレイテッド |
抗cct5結合分子およびその使用方法
|
SG11202005732XA
(en)
|
2017-12-19 |
2020-07-29 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
AU2018388997A1
(en)
|
2017-12-20 |
2020-07-09 |
Lentigen Technology, Inc. |
Compositions and methods for treating HIV/AIDS with immunotherapy
|
MA51666A
(fr)
|
2018-01-24 |
2020-12-02 |
Genmab Bv |
Variants polypeptidiques et leurs utilisations
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
MX2020009469A
(es)
|
2018-03-13 |
2021-01-29 |
Zymeworks Inc |
Conjugados de anticuerpo y farmaco anti-her2 biparatopicos y metodos de uso.
|
EP3768324A1
(de)
|
2018-03-22 |
2021-01-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur modulierung der angeborenen lymphoidzellaktivität, antikörper-arzneimittelkonjugate und verwendungen in der therapie
|
MA52135A
(fr)
|
2018-03-23 |
2021-01-27 |
Seagen Inc |
Utilisation de conjugués anticorps-médicament comprenant des agents de rupture de tubuline pour traiter une tumeur solide
|
CA3095443A1
(en)
|
2018-03-28 |
2019-10-03 |
Axon Neuroscience Se |
Antibody-based methods of detecting and treating alzheimer's disease
|
AU2019247415A1
(en)
|
2018-04-04 |
2020-10-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
EP3552631A1
(de)
|
2018-04-10 |
2019-10-16 |
Inatherys |
Antikörper-arzneimittel-konjugate und deren verwendungen zur behandlung von krebs
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
JP2021521202A
(ja)
|
2018-04-13 |
2021-08-26 |
ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
固形腫瘍の治療のための標的化されたアマトキシン複合体
|
CA3097593A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
JP2021520829A
(ja)
|
2018-04-18 |
2021-08-26 |
ゼンコア インコーポレイテッド |
IL−15/IL−15RA Fc融合タンパク質およびTIM−3抗原結合ドメインを含む、TIM−3標的化ヘテロ二量体融合タンパク質
|
US11485741B2
(en)
|
2018-04-24 |
2022-11-01 |
Bristol-Myers Squibb Company |
Macrocyclic toll-like receptor 7 (TLR7) agonists
|
WO2019217455A1
(en)
|
2018-05-07 |
2019-11-14 |
Genmab A/S |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
MX2020011176A
(es)
|
2018-05-07 |
2020-11-12 |
Genmab As |
Metodos para tratar cancer con una combinacion de un anticuerpo anti-molecula de muerte programada 1 y un conjugado de anticuerpo anti-factor tisular-medicamento.
|
JP7257422B2
(ja)
|
2018-05-18 |
2023-04-13 |
第一三共株式会社 |
抗muc1抗体-薬物コンジュゲート
|
CA3104729A1
(en)
|
2018-05-22 |
2019-11-28 |
Avidea Technologies, Inc. |
Improved methods of manufacturing peptide-based vaccines
|
MX2020012674A
(es)
|
2018-05-29 |
2021-02-09 |
Bristol Myers Squibb Co |
Porciones autoinmolantes modificadas para usarse en profarmacos y conjugados y metodos de uso y fabricacion.
|
KR20210016375A
(ko)
|
2018-06-01 |
2021-02-15 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
스플라이싱 조절제 항체-약물 접합체 및 사용 방법
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
WO2019240287A1
(ja)
|
2018-06-14 |
2019-12-19 |
味の素株式会社 |
抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
|
AU2019285354A1
(en)
|
2018-06-14 |
2021-01-07 |
Ajinomoto Co., Inc. |
Substance having affinity for antibody, and compound or salt thereof having bioorthogonal functional group
|
PE20211091A1
(es)
|
2018-07-02 |
2021-06-14 |
Amgen Inc |
Proteina de union al antigeno anti-steap1
|
EP3830259A4
(de)
|
2018-08-02 |
2022-05-04 |
Dyne Therapeutics, Inc. |
Auf muskel abzielende komplexe und ihre verwendungen zur behandlung von fazioskapulohumeraler muskeldystrophie
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
CN112955153A
(zh)
|
2018-08-02 |
2021-06-11 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗肌养蛋白病的用途
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
US11554120B2
(en)
|
2018-08-03 |
2023-01-17 |
Bristol-Myers Squibb Company |
1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
JP2022511337A
(ja)
|
2018-09-19 |
2022-01-31 |
インサーム (インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシェ メディカル) |
免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物
|
CN113260630A
(zh)
|
2018-09-20 |
2021-08-13 |
莱蒂恩技术公司 |
用于用抗cd123免疫治疗来治疗癌症的组合物和方法
|
KR20210062005A
(ko)
|
2018-09-20 |
2021-05-28 |
다이이찌 산쿄 가부시키가이샤 |
항 her3 항체-약물 콘쥬게이트 투여에 의한 her3 변이암의 치료
|
EP3626265A1
(de)
|
2018-09-21 |
2020-03-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-human-cd45rc-antikörper und verwendungen davon
|
US10822412B2
(en)
|
2018-09-26 |
2020-11-03 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy
|
CA3113782A1
(en)
|
2018-10-03 |
2020-04-09 |
Avidea Technologies, Inc. |
Aromatic ring substituted amphiphilic polymers as drug delivery systems
|
WO2020072821A2
(en)
|
2018-10-03 |
2020-04-09 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
EP3870235A1
(de)
|
2018-10-24 |
2021-09-01 |
F. Hoffmann-La Roche AG |
Konjugierte chemische abbauauslöser und verwendungsverfahren
|
TW202034958A
(zh)
|
2018-10-30 |
2020-10-01 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子(vegf)抗體與抗組織因子(tf)抗體-藥物共軛體之組合以治療癌症之方法
|
EP3882261A4
(de)
|
2018-10-31 |
2023-02-08 |
Ajinomoto Co., Inc. |
Verbindung mit substanz mit affinität für antikörper, spaltstelle und reaktive gruppe oder salz davon
|
US20220025058A1
(en)
|
2018-11-06 |
2022-01-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
|
WO2020113108A1
(en)
|
2018-11-30 |
2020-06-04 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd38 immunotherapy
|
KR20210100668A
(ko)
|
2018-12-06 |
2021-08-17 |
제넨테크, 인크. |
항-CD79b 면역접합체, 알킬화제 및 항-CD20 항체를 포함하는 미만성 큰 B-세포 림프종의 조합 요법
|
US20220031859A1
(en)
|
2018-12-13 |
2022-02-03 |
Eisai R&D Management Co., Ltd. |
Herboxidiene antibody-drug conjugates and methods of use
|
EP3894543A1
(de)
|
2018-12-14 |
2021-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Isolierte humane mhc-abgeleitete peptide und verwendungen davon zur stimulierung und aktivierung der suppressiven funktion von cd8cd45rc + cd45rc low tregs
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
AU2020219732A1
(en)
|
2019-02-05 |
2021-08-05 |
Seagen Inc. |
Anti-CD228 antibodies and antibody-drug conjugates
|
JP2022523946A
(ja)
|
2019-03-01 |
2022-04-27 |
ゼンコア インコーポレイテッド |
Enpp3およびcd3に結合するヘテロ二量体抗体
|
JP2022524507A
(ja)
|
2019-03-06 |
2022-05-06 |
レンティジェン・テクノロジー・インコーポレイテッド |
自己駆動型キメラ抗原受容体を用いてがんを処置するための組成物および方法
|
JP2022528020A
(ja)
|
2019-03-19 |
2022-06-07 |
フンダシオ プリバダ インスティトゥト ディンベスティガシオ オンコロジカ デ バル エブロン |
癌の治療のための併用療法
|
CN114174340A
(zh)
|
2019-03-20 |
2022-03-11 |
加利福尼亚大学董事会 |
密封蛋白-6抗体和药物缀合物
|
WO2020214858A1
(en)
|
2019-04-17 |
2020-10-22 |
Avidea Technologies, Inc. |
Compositions and methods of manufacturing star polymers for ligand display and/or drug delivery
|
EP3958908A1
(de)
|
2019-04-24 |
2022-03-02 |
Heidelberg Pharma Research GmbH |
Amatoxin-antikörper-wirkstoff-konjugate und verwendungen davon
|
TW202108178A
(zh)
|
2019-05-14 |
2021-03-01 |
美商建南德克公司 |
使用抗CD79b免疫結合物治療濾泡性淋巴瘤之方法
|
EP3976653A1
(de)
|
2019-05-30 |
2022-04-06 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit anti-bcma-immuntherapie
|
WO2020247054A1
(en)
|
2019-06-05 |
2020-12-10 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
GB201908128D0
(en)
|
2019-06-07 |
2019-07-24 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
CN110339181A
(zh)
*
|
2019-07-02 |
2019-10-18 |
中国药科大学 |
一种基于点击反应的pH响应型纳米制剂及其制法和应用
|
MX2022000174A
(es)
|
2019-07-02 |
2022-05-20 |
Us Health |
Anticuerpos monoclonales que se enlazan a egfrviii y sus usos.
|
TW202120551A
(zh)
|
2019-08-12 |
2021-06-01 |
美商普瑞諾生物科技公司 |
藉由adcc靶向cd39表現細胞促進及增強t細胞介導免疫反應之方法及組合物
|
JP2022550816A
(ja)
|
2019-10-04 |
2022-12-05 |
シージェン インコーポレイテッド |
抗pd-l1抗体および抗体-薬物コンジュゲート
|
WO2021064184A1
(en)
|
2019-10-04 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
TW202122114A
(zh)
|
2019-10-18 |
2021-06-16 |
美商建南德克公司 |
使用抗CD79b 免疫偶聯物治療彌漫性大B 細胞淋巴瘤的方法
|
EP3812008A1
(de)
|
2019-10-23 |
2021-04-28 |
Gamamabs Pharma |
Amh-kompetitiver antagonistischer antikörper
|
AU2020380732A1
(en)
|
2019-11-07 |
2022-06-02 |
Genmab A/S |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
TW202131954A
(zh)
|
2019-11-07 |
2021-09-01 |
丹麥商珍美寶股份有限公司 |
利用鉑類劑與抗組織因子抗體-藥物共軛體之組合來治療癌症之方法
|
EP4072682A1
(de)
|
2019-12-09 |
2022-10-19 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antikörper mit spezifität gegen her4 und verwendungen davon
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
EP4087657A1
(de)
|
2020-01-08 |
2022-11-16 |
Synthis Therapeutics, Inc. |
Alk5-inhibitoren, konjugate und verwendungen davon
|
AU2021213421A1
(en)
|
2020-01-31 |
2022-06-23 |
Innate Pharma |
Treatment of cancer
|
TW202206111A
(zh)
|
2020-04-24 |
2022-02-16 |
美商建南德克公司 |
使用抗cd79b免疫結合物之方法
|
EP3909612A1
(de)
|
2020-05-12 |
2021-11-17 |
Life Science Inkubator Betriebs GmbH & Co. KG |
Zusammensetzung von nanopartikeln
|
EP4149558A1
(de)
|
2020-05-12 |
2023-03-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neues verfahren zur behandlung von kutanen t-zell-lymphomen und tfh-abgeleiteten lymphomen
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
US20230302050A1
(en)
|
2020-05-20 |
2023-09-28 |
Institut Curie |
Single Domain Antibodies and Their Use in Cancer Therapies
|
KR20230020441A
(ko)
|
2020-06-05 |
2023-02-10 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
항-bcma 항체-약물 컨쥬게이트 및 이용 방법
|
JPWO2021251358A1
(de)
|
2020-06-09 |
2021-12-16 |
|
|
AU2021296423A1
(en)
|
2020-06-22 |
2023-02-02 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy
|
EP4171652A1
(de)
|
2020-06-29 |
2023-05-03 |
Genmab A/S |
Antikörper-wirkstoff-konjugate gegen den gewebefaktor und deren verwendung bei der behandlung von krebs
|
TW202216212A
(zh)
|
2020-07-17 |
2022-05-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物之製造方法
|
TW202216215A
(zh)
|
2020-07-21 |
2022-05-01 |
美商建南德克公司 |
Brm降解之抗體結合化學誘導物及其方法
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
US20230323299A1
(en)
|
2020-08-03 |
2023-10-12 |
Inserm (Institut National De La Santé Et De La Recherch Médicale) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
IL300176A
(en)
|
2020-08-04 |
2023-03-01 |
Seagen Inc |
Anti-CD228 antibodies and antibody-drug conjugates
|
WO2022043256A1
(en)
|
2020-08-23 |
2022-03-03 |
Cobiores Nv |
Synergistic combinations of anticancer drugs linked to a tetrapeptidic moiety and immunotherapeutic agents
|
CN112062855A
(zh)
|
2020-08-26 |
2020-12-11 |
康诺亚生物医药科技(成都)有限公司 |
一种含有衔接器的药物治疗剂的开发和应用
|
JP2023541816A
(ja)
|
2020-08-27 |
2023-10-04 |
イノージ・セラピューティクス・コーポレイション |
自己免疫性疾患および癌を治療するための方法および組成物
|
EP3970752A1
(de)
|
2020-09-17 |
2022-03-23 |
Merck Patent GmbH |
Moleküle mit löslichkeitsmarkierung und zugehörige verfahren
|
WO2022066635A1
(en)
|
2020-09-22 |
2022-03-31 |
Avidea Technologies, Inc. |
Compositions and methods of manufacturing amphiphilic block copolymers that form nanoparticles in situ
|
EP4229090A1
(de)
|
2020-10-16 |
2023-08-23 |
Université d'Aix-Marseille |
Anti-gpc4-einzeldomänenantikörper
|
EP4228701A1
(de)
|
2020-10-19 |
2023-08-23 |
Vaccitech North America, Inc. |
Sternpolymer-arzneimittelkonjugate
|
JP7349578B2
(ja)
|
2020-10-27 |
2023-09-22 |
エルシダ オンコロジー, インコーポレイテッド |
葉酸受容体に標的化されたナノ粒子薬物コンジュゲートおよびその使用
|
WO2022099026A1
(en)
|
2020-11-05 |
2022-05-12 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
CN114524878A
(zh)
|
2020-11-23 |
2022-05-24 |
康诺亚生物医药科技(成都)有限公司 |
一种双特异性抗体及其用途
|
CA3196198A1
(en)
|
2020-11-25 |
2022-06-02 |
Manel KRAIEM |
Treatment of cancer
|
CN114573703A
(zh)
|
2020-12-02 |
2022-06-03 |
康诺亚生物医药科技(成都)有限公司 |
一种t细胞衔接器治疗剂的开发和应用
|
CN114573702A
(zh)
|
2020-12-02 |
2022-06-03 |
康诺亚生物医药科技(成都)有限公司 |
一种新型肿瘤衔接器治疗药物的开发和应用
|
EP4015004A1
(de)
|
2020-12-18 |
2022-06-22 |
Phi Pharma SA |
Proteoglykanspezifische verzweigte peptide
|
AU2021405744A1
(en)
|
2020-12-22 |
2023-08-03 |
Cobiores Nv |
Compounds comprising a tetrapeptidic moiety
|
CN114685657A
(zh)
|
2020-12-31 |
2022-07-01 |
康诺亚生物医药科技(成都)有限公司 |
一种功能增强型抗体阻断剂的开发及其应用
|
WO2022152862A1
(en)
|
2021-01-14 |
2022-07-21 |
Institut Curie |
Her2 single domain antibodies variants and cars thereof
|
AU2022207278A1
(en)
|
2021-01-18 |
2023-08-03 |
Ajinomoto Co., Inc. |
Compound or salt thereof, and antibody obtained therefrom
|
WO2022154116A1
(ja)
|
2021-01-18 |
2022-07-21 |
味の素株式会社 |
化合物またはその塩、およびそれらにより得られる抗体
|
UY39610A
(es)
|
2021-01-20 |
2022-08-31 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
WO2022167664A1
(en)
|
2021-02-07 |
2022-08-11 |
Cobiores Nv |
Compounds comprising a tetrapeptidic moiety
|
KR20230156079A
(ko)
|
2021-03-09 |
2023-11-13 |
젠코어 인코포레이티드 |
Cd3과 cldn6에 결합하는 이종이량체 항체
|
EP4305065A1
(de)
|
2021-03-10 |
2024-01-17 |
Xencor, Inc. |
Cd3 und gpc3 bindende heterodimere antikörper
|
KR20230154853A
(ko)
|
2021-03-11 |
2023-11-09 |
아지노모토 가부시키가이샤 |
화합물 또는 이의 염, 및 이들에 의해 얻어지는 항체
|
EP4310096A1
(de)
|
2021-03-16 |
2024-01-24 |
Ajinomoto Co., Inc. |
Komplex oder salz davon und verfahren zur herstellung davon
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
KR20240012352A
(ko)
|
2021-03-23 |
2024-01-29 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
T 세포 림프종의 진단 및 치료 방법
|
KR20220136267A
(ko)
|
2021-03-30 |
2022-10-07 |
주식회사 레고켐 바이오사이언스 |
인간 cldn18.2에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
|
WO2022214681A1
(en)
|
2021-04-09 |
2022-10-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of anaplastic large cell lymphoma
|
WO2022217022A1
(en)
|
2021-04-10 |
2022-10-13 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
EP4079327A1
(de)
*
|
2021-04-22 |
2022-10-26 |
Centaurus Polytherapeutics |
Nutzlasten für arzneimittelkonjugate und deren verwendung zur behandlung von krebs
|
CN117203238A
(zh)
|
2021-04-23 |
2023-12-08 |
普方生物制药美国公司 |
Cd70结合剂、其偶联物及其使用方法
|
CA3218170A1
(en)
|
2021-05-12 |
2022-11-17 |
Jamie Harue HIRATA |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
KR20240013732A
(ko)
|
2021-05-26 |
2024-01-30 |
옥스포드 바이오테라퓨틱스 리미티드 |
항-cd205 항체 및 면역 체크포인트 억제제를 포함하는 약학적 조합물
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
US11771776B2
(en)
|
2021-07-09 |
2023-10-03 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
US11672872B2
(en)
|
2021-07-09 |
2023-06-13 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor antibody and uses thereof
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
WO2023019092A1
(en)
|
2021-08-07 |
2023-02-16 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
WO2023041717A1
(en)
|
2021-09-16 |
2023-03-23 |
Aboleris Pharma |
Anti-human cd45rc binding domains and uses thereof
|
WO2023056069A1
(en)
|
2021-09-30 |
2023-04-06 |
Angiex, Inc. |
Degrader-antibody conjugates and methods of using same
|
AU2022356491A1
(en)
|
2021-10-01 |
2024-03-14 |
Unichem Laboratories Limited |
Recombinant glycan binding proteins and its use
|
WO2023089314A1
(en)
|
2021-11-18 |
2023-05-25 |
Oxford Biotherapeutics Limited |
Pharmaceutical combinations
|
WO2023092099A1
(en)
|
2021-11-19 |
2023-05-25 |
Ardeagen Corporation |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
WO2023110937A1
(en)
|
2021-12-14 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
WO2023111350A2
(en)
|
2021-12-17 |
2023-06-22 |
3B Pharmaceuticals Gmbh |
Carbonic anhydrase ix ligands
|
WO2023147329A1
(en)
|
2022-01-26 |
2023-08-03 |
Genentech, Inc. |
Antibody-conjugated chemical inducers of degradation and methods thereof
|
WO2023144303A1
(en)
|
2022-01-31 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
US11590169B1
(en)
|
2022-03-02 |
2023-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
WO2023194539A1
(en)
|
2022-04-07 |
2023-10-12 |
Heidelberg Pharma Research Gmbh |
Methods of improving the therapeutic index of amatoxin-antibody conjugates
|
WO2023198648A1
(en)
|
2022-04-11 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t-cell malignancies
|
WO2023198874A1
(en)
|
2022-04-15 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
WO2023215737A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|
WO2023213960A1
(en)
|
2022-05-06 |
2023-11-09 |
Genmab A/S |
Methods of treating cancer with anti-tissue factor antibody-drug conjugates
|
WO2023227660A1
(en)
|
2022-05-25 |
2023-11-30 |
Innate Pharma |
Nectin-4 binding agents
|
WO2024003310A1
(en)
|
2022-06-30 |
2024-01-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of acute lymphoblastic leukemia
|
WO2024018046A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Garp as a biomarker and biotarget in t-cell malignancies
|
WO2024026107A2
(en)
|
2022-07-28 |
2024-02-01 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
WO2024023283A1
(en)
|
2022-07-29 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
|
WO2024044743A1
(en)
|
2022-08-26 |
2024-02-29 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy
|